that bound to the endothelium, 3) cells that had migrated through the endothelium, and then counted by microscope. Experiments in which EC and PBMC as well as only EC were treated with A771726 (in the absence or presence of uridine) were compared to simultaneously performed control experiments. No increased toxicity on the PBMC treated with the doses of A771726 used in our experiments, was observed. Paired T Test was used for statistical evaluations.

Results 24 h incubation of PBMC and EC with A771726 induced a significant decrease in TEM ($8 \pm 6\%$ vs. $16 \pm 12\%$ migrated cells, $p = 0.004$). Furthermore, 24 h preincubation of solely the EC with A771726 inhibited the TEM of untreated PBMC ($11 \pm 9\%$ vs. $15 \pm 8\%$ migrated cells, $p = 0.043$), indicating direct effects of A771726 on EC. Uridine significantly reversed the decrease in TEM when incubating PBMC and EC with both uridine and A771726 ($15 \pm 10\%$ vs $9 \pm 7\%$ migrated cells, $p = 0.023$).

Conclusion Our results demonstrate that leflunomide may have direct anti-inflammatory effects by inhibiting the extravasation of PBMC, possibly via downregulation of adhesion molecules on EC and mononuclear cells. These data suggest, that leflunomide, besides its influences on lymphocyte proliferation, also reduces recruitment of mononuclear cells to inflammatory sites.

OP0006 **DISTINCT MECHANISMS OF IL-1 INHIBITION REVEALED BY *IN VITRO* MODELLING OF IL-1 RECEPTOR ACCESSORY PROTEIN INTERACTIONS WITH IL-1/IL-1 RECEPTOR COMPLEX**

BC Varnum, A Witte, C Vezina, X Qian. *Pharmacology, Amgen, Thousand Oaks, USA*

10.1136/annrheumdis-2001.520

Background IL-1 stimulates cellular responses by interacting with a heterodimeric receptor complex comprised of IL-1 receptor type I (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP). IL-1 first binds IL-1RI then IL-1RAcP is recruited to this complex. Inhibitors of IL-1 bioactivity may function through inhibiting any aspect of this complex formation. Understanding the mechanism of inhibition of specific inhibitors can shed light on the nature of the interfaces that define a high affinity site for IL-1RAcP binding.

Objectives To model the interaction of IL-1 Receptor Accessory Protein with IL-1 bound IL-1 Receptor using purified recombinant proteins, and assess the mechanism of antagonism for IL-1 inhibitors.

Methods The extracellular domain of IL-1RAcP was expressed and purified. The interaction of IL-1RAcP with IL-1RI, IL-1 and IL-1RI/IL-1 complex was explored in binding assays. Antibodies to IL-1 and IL-1RI have been used to investigate the roles of individual components of the complex. IL-1 bioassays have been developed to validate the *in vitro* findings.

Results As expected, IL-1RAcP did not interact with either IL-1 or IL-1RI alone, even at high concentrations (100 nM), however, binding to complex was measured to be high affinity (~ 1 nM). Furthermore, purified IL-1RAcP enhanced binding of IL-1 to receptor. Antibodies to IL-1b have been identified which block binding of IL-1/IL-1RI to IL-1RAcP but fail to influence IL-1 binding to receptor.

Conclusion The observation that anti-IL-1beta antibodies can selectively block binding of IL-1RAcP demonstrates a novel mechanism of IL-1 inhibition and supports the hypothesis that IL-1 makes direct contacts with IL-1RAcP. Since IL-1 does not

demonstrate any measurable affinity for IL-1RAcP when not bound to IL-1RI, it is likely that additional elements of the binding site are comprised of IL-1RI residues. Future studies mapping the elements of IL-1RAcP involved in the contact points will further define the binding interface.

OP0126 **CD28 DIRECTLY INITIATES IL-4 GENE TRANSCRIPTION AND INDUCES TCR INDEPENDENT TH2 CELL DIFFERENTIATION IN HUMAN MEMORY CD4 T CELLS**

¹A Skapenko, ²PE Lipsky, ¹JR Kalden, ¹H Schulze-Koops. ¹Department of Internal Medicine III, University Erlangen-Nuremberg, Erlangen, Germany; ²NIAMS, NIH, Bethesda, USA

10.1136/annrheumdis-2001.521

Background Evidence suggests that human autoimmune diseases might be driven by pro-inflammatory Th1 cells whereas immunomodulatory Th2 cells are rarely found. Th1 dominated immunity might result from disordered regulation of memory T cell differentiation with insufficient generation of Th2 cells to down-modulate inflammation.

Objectives To gain insights into the mechanisms regulating human Th2 effector differentiation, we investigated Th2 differentiation in isolated human CD4^{pos} naive and memory T cells *in vitro*.

Methods A cell culture system was employed that permitted Th2 cell differentiation after short term priming. The phenotype of freshly isolated and primed T cells was determined by cytometric analysis of intracellular cytokines. Analysis of mRNA was performed using semiquantitative RT-PCR.

Results Th2 cells could be generated from resting cord blood naive CD4^{pos} T cells by priming with anti-CD3 and anti-CD28. Exogenous IL-4 was not required for Th2 cell differentiation from naive T cells and did only marginally increase Th2 priming efficiency. In striking contrast, co-stimulation of memory T cells through CD3 and CD28 increased Th2 cell frequencies only minimally if at all. When recombinant IL-4 was added during priming, an increase in Th2 effectors was noted. Of marked interest, however, significant Th2 cell differentiation was induced by priming of CD4^{pos} memory T cells with anti-CD28 in the absence of TCR mediated signals. CD28 induced Th2 cell differentiation was dependent on IL-4 as neutralising of IL-4 inhibited the generation of Th2 effectors. As no exogenous IL-4 was required for CD28 mediated Th2 cell differentiation, the impact of CD28 ligation on IL-4 gene transcription in memory T cells was evaluated. IL-4 mRNA levels increased after CD28 engagement. To distinguish whether the increase in IL-4 mRNA levels after anti-CD28 stimulation resulted from initiation of transcription or from stabilisation of preformed mRNA, purified CD4^{pos} memory T cells were stimulated with anti-CD28 in the presence or absence of actinomycin D. Actinomycin D completely inhibited the CD28 induced increase of IL-4 mRNA. Furthermore, when actinomycin was added when IL-4 mRNA levels were already increased, IL-4 mRNA levels declined markedly with a half-life of app. 60 min, indicating that the increase in IL-4 mRNA after CD28 engagement is caused to a significant extent by the induction of IL-4 gene transcription.

Conclusion CD28 ligation directly initiated IL-4 gene transcription and induced Th2 differentiation in a TCR independent manner in memory but not in naive T cells. TCR independent generation of Th2 effectors might provide a way to control Th1 dominated cellular inflammation.